N/A N=171 Psoriatic Arthritis Research Collaborative: Biologic Sub-Study
Psoriatic Arthritis
Primary: Patient Function Response to Biologic Therapy as Measured by RAPID3 — -1.11 change in score
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=52 Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients With Psoriasis Severe or Moderate With Adalimumab Treatment
Psoriasis · Psoriatic Arthritis
Primary: Percentage of Participants Who Developed Psoriatic Arthritis (PsA) — 47.4; 35.7; 17.3; 10.3 Percentage of participants
Phase 4 N=1,013 Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology Practice
Psoriasis · Psoriatic Arthritis
Primary: Percentage of Participants With Psoriatic Arthritis (PsA) Based on Physical Examination, Medical History and Laboratory Results — 30.0 Percentage of participants
Phase 2 N=165 Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy
Arthritis, Psoriatic
Primary: Percent of Participants Achieving American College of Rheumatology Criteria 20% Response Rate (ACR20) — 29.3; 46.3; 52.4; 39.0 percentage of participants
Phase 4 N=308 Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.
Arthritis, Psoriatic
Primary: Percentage of Participants Who Achieved a Clinical State of Minimal Disease Activity (MDA-Joints) Response at Week 16 — 16.0; 33.9 percentage of participants — p=0.0008
Phase 3 N=504 Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
Psoriatic Arthritis
Primary: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16 — 19.0; 30.4; 38.1 percentage of participants — p=0.0001
Phase 3 N=528 Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
Psoriatic Arthritis
Primary: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16 — 15.9; 28.0; 30.7 percentage of participants — p=0.0062
N/A N=21 Psoriasis Inflammation and Systemic Co Morbidities
Psoriasis
Primary: Change in Histology
Phase 3 N=424 Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis
Psoriatic Arthritis
Primary: Proportion of ACR 20 Responders at Day 169 — 39.4; 22.3 Percentage of participants — p=<0.001
Phase 3 N=219 Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
Psoriatic Arthritis
Primary: Percentage of Participants Who Achieved an American College of Rheumatology 20% (ACR20) Response at Week 16 — 20.2; 38.2 percentage of participants — p=0.0040
N/A N=145 The Effect of n-3 Polyunsaturated Fatty Acids in Patients With Psoriatic Arthritis
Psoriatic Arthritis
Primary: Change in Heart Rate Variability (HRV) Measure — 13.38; -13.48 ms
N/A N=116 Effectiveness of Treatment With Tofacitinib in Patients With Psoriatic Arthritis in Routine Clinical Practice
Psoriatic Arthritis
Primary: Percentage of Participants Who Achieved Low Disease Activity (LDA) Based on Psoriatic Arthritis Disease Activity Score (PASDAS) at Month 6 — 43.1; 46.9; 33.4; 4.0…
Phase 2 N=126 Phase II Study of Apremilast (CC-10004) in Adults With in Psoriatic Arthritis
Psoriatic Arthritis
Primary: Percentage of Participants With a Modified American College of Rheumatology 20% (ACR 20) Response at Week 12 — 35.8; 43.5; 11.8 percentage of participants — p=0.002
Phase 3 N=405 A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic Arthritis
Arthritis, Psoriatic
Primary: American College of Rheumatology (ACR) 20 Response at Week 14 — 10; 74; 66; 140 Participants — p=<0.001
Phase 3 N=851 Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis
Psoriatic Arthritis
Primary: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24 — 50.7; 60.9; 65.0 percentage of participants — p=0.005
Phase 4 N=63 Subclinical Cardiovascular Disease in Psoriatic Disease
Cardiovascular Diseases · Myocardial Infarction · Atherosclerotic Cardiovascular Disease
Primary: Mean Fold Change in Brachial Vein Endothelial Inflammatory Transcript — 8.6; 2.8 Fold Change
Phase 3 N=414 24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis
Psoriatic Arthritis
Primary: Proportion of Patients Achieving American College of Rheumatology 20 (ACR20) Response Criteria on Secukinumab Versus Placebo at Week 24 — 58; 67; 22 Participants
N/A N=503 AsseSSing Impact in pSoriatic Treatment
Psoriatic Arthritis
Primary: Number of Patients Undergoing Treatment Escalation — 160 Participants
Phase 3 N=480 A Study of Golimumab in Participants With Active Psoriatic Arthritis
Arthritis, Psoriatic
Primary: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 14 — 21.8; 75.1 Percentage of Participants — p=<0.001
N/A N=4,635 Efficacy and Safety of Humira® in Patients With Psoriatic Arthritis in Normal Medical Practice
Psoriatic Arthritis
Primary: Mean Change From Baseline in Disease Activity Score (DAS)28 — -1.7; -1.9; -1.9; -2.0 score on a scale
Phase 4 N=752 Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis
Psoriatic Arthritis
Primary: Number of Patients Achieving "Clear" or "Almost Clear" on Physician Global Assessment (PGA) of Psoriasis — 176; 119 participants
N/A N=149 Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Dermatologists
Arthritis, Psoriatic · Psoriasis · Skin Diseases, Papulosquamous
Primary: Percentage of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) — 24.2; 1.3 percentage of participants
N/A N=1,291 Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Rheumatologists
Arthritis, Psoriatic · Psoriasis · Skin Diseases, Papulosquamous
Primary: Percentage of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) — 38.1; 6.0 percentage of participants
Phase 3 N=505 PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
Psoriatic Arthritis
Primary: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16 — 18.3; 28.4; 40.7 percentage of participants — p=<0.0001
Phase 4 N=123 A Study to Evaluate the Impact of Apremilast on Magnetic Resonance Imaging (MRI) Outcomes in Adults With Psoriatic Arthritis
Psoriatic Arthritis
Primary: Change From Baseline in the Composite Score of BME, Synovitis, and Tenosynovitis Assessed by PsAMRIS at Week 24 — -2.32 score on a scale
Phase 3 N=394 Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
Psoriatic Arthritis
Primary: Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20): Month 3 — 49.62; 46.97; 23.66 Percentage…
Phase 3 N=1,705 A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)
Psoriatic Arthritis
Primary: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 — 36.2; 65.0; 70.6; 78.5 percentage of participants — p=<0.0001
N/A N=96 Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice
Rheumatoid Arthritis · Ankylosing Spondylitis · Psoriatic Arthritis
Primary: Change From Baseline in the Beliefs About Medicines Questionnaire (BMQ) Specific Score at 12 Months — -1.4 units on a scale
Phase 3 N=341 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis
Arthritis, Psoriatic
Primary: Number of Participants With American College of Rheumatology 20 (ACR20) Response — 47; 45; 21 Participants — p=0.0002
N/A N=141 A Study to Learn About the Study Medicine (Called Tofacitinib) in People With Psoriatic Arthritis
Psoriatic Arthritis
Primary: Change From Baseline to 6 Months in Tender Joint Count (68) — -2.5; -3.2; -2.0 Tender joints